Skip to main
ACLX
ACLX logo

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 11%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. has demonstrated robust sales growth, with Carvykti averaging a 32% increase in quarterly sales over the past 12 quarters, indicating a strong market demand for its products. Additionally, the rising proportion of community physicians capable of administering CAR T therapies, growing from 29% to 47% within two years, suggests an expanding accessibility and acceptance of these treatments. Positive clinical trial data for anito-cel, along with projections for significant market share and sales growth within the BCMA CAR T market, further underpin a favorable outlook for Arcellx's stock.

Bears say

Arcellx Inc faces a negative outlook primarily due to below-consensus sales estimates for its anito-cel product in the CAR T market, forecasting $11.5 billion in 2035 sales compared to a consensus expectation of $16.5 billion. The company also confronts significant execution risks related to its drug pipeline, coupled with potential political pressures regarding drug pricing and a turbulent biotechnology funding environment. Additionally, despite a substantial patient pool and promising therapy data, barriers affecting patient access to CAR T treatments substantially hinder market adoption, further contributing to financial uncertainties.

Arcellx (ACLX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 11% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Arcellx (ACLX) has a Strong Buy consensus rating as of Nov 8, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $117.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $117.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.